Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment

CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Project ID: GENC0609

The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA) Program supports and is committed to the transparency of its review process. Therefore, invited peer review comments and public review comments are publicly posted on the TA Program Web site within 3 months after the associated final report is posted.

This document presents the peer review comments and public review comments sent in response to the draft report, Update of Genetic Tests for Non-Cancer and Cancer Diseases and Conditions, which was made available for comment on the AHRQ Web site

• View the print version (PDF file, 176 KB).

Tables

• Table 1. Invited Peer Reviewer Comments.
• Table 2. Public Reviewer Comments.